News & Events

Nuon Therapeutics, Inc., a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, today announced the appointment of Michael M. Kitt, M.D., to the position of Chief Medical Officer.

"Dr. Kitt is an experienced clinician who will lead Nuon's clinical development programs
in the area of autoimmune disease. Michael has been responsible for the successful
completion of clinical trials in a variety of clinical indications and will be able to apply
his extensive knowledge and depth of expertise to our programs," said Rodney Pearlman,
Ph.D., President and CEO of Nuon Therapeutics. "Michael has functional experience in
multiple areas involved in drug development and has a keen grasp of the issues and
challenges in taking a drug through the clinical development process. He also has
considerable regulatory experience, which will be invaluable as we advance our lead
compound, tranilast, into clinical trials."

Dr. Kitt was most recently Senior Vice President, Development at Theravance, Inc.,
where he had responsibilities for Clinical Research, Medical Affairs, Biostatistics & Data
Management, Regulatory Affairs, Preclinical, Safety & Toxicology and Project
Management. He was involved in filing numerous INDs, taking one compound through
to NDA stage. Prior to this, Dr. Kitt was Vice President of Clinical Research at COR
Therapeutics, where he was responsible for the clinical program for Integrilin, which was
approved for two indications in both the U.S. and Europe. Previously, he was Sr. Vice
President for Clinical Research at Sterling-Winthrop, where he was involved in the
clinical development of a number of novel compounds. Prior to that, at the Upjohn
Company, he held numerous positions in the clinical field, including several years in the
European Clinical Research Office in Belgium. Dr. Kitt has a B.S. in Chemistry from the
Polytechnic University in New York and an M.D. from NYU.